Novo Nordisk's Record Profits and Market Value Surge Amid Obesity Drug Boom

Novo Nordisk reported a strong fourth quarter and full-year earnings, with total sales up 36% and the company's valuation surpassing $500 billion, largely driven by the success of its blockbuster drugs Ozempic and Wegovy. CFO Knudsen expressed delight over the results and the company's ability to increase dividends for investors. Despite supply issues, particularly with Wegovy, the company is ramping up production to meet demand. Novo's stock has surged nearly 60% in the past year, and its GLP-1 products brought in nearly $24 billion in 2023.